InflaRx Doubles Its Share Count to Secure $150 Million War Chest for Kidney Drug Push

InflaRx has pulled off a dramatic financial restructuring, placing 75 million new shares at $2.00 apiece to raise gross proceeds of $150 million. The capital injection, led by Guggenheim Securities as bookrunner, comes as the biotech group pivots away from commercializing its first drug in the US and doubles down on oral therapies for rare kidney diseases.

After underwriting fees, the company will pocket approximately $140.5 million — a significant boost to its balance sheet, which held just under €40 million in cash at the end of March. The net loss for the first quarter of 2026 narrowed to €5.6 million, compared with €8.3 million in the same period a year earlier, as operating expenses plummeted to €7.5 million following the termination of marketing efforts for Gohibic.

The fundraising transforms InflaRx’s capital structure. Outstanding shares will balloon from 72.3 million to 147.3 million, more than doubling the equity base. Yet investors have taken the dilution in stride: the stock climbed 6% on the day of the transaction’s close to $2.65, and has surged 26% over the past week.

Should investors sell immediately? Or is it worth buying InflaRx?

The fresh cash buys time for a high-stakes strategic pivot. InflaRx is now betting its future on Izicopan, an oral drug candidate targeting ANCA-associated vasculitis and IgA nephropathy. First clinical data are expected next year, with a Capital Markets Day planned for the summer to flesh out the long-term roadmap. The company is also actively seeking partners for its programs in pyoderma gangrenosum and hidradenitis suppurativa.

Despite the improved liquidity, the company’s financial filings flag a material uncertainty about its ability to continue as a going concern. The absence of recurring revenue and the heavy costs of upcoming clinical trials mean InflaRx will need additional financing or partnerships to stay afloat beyond 2027 — the horizon its current reserves are expected to cover.

Management is set to detail the clinical strategy in a webcast later today, as the biotech attempts to convince the market that its oral pipeline can deliver where its first commercial product could not.

Ad

InflaRx Stock: New Analysis - 8 May

Fresh InflaRx information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated InflaRx analysis...

en | NL0012661870 | INFLARX | boerse | 69294180 |